Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 8 studies | 30% ± 12% | |
pericyte | 8 studies | 26% ± 17% | |
adipocyte | 5 studies | 27% ± 9% | |
endothelial cell | 4 studies | 33% ± 17% | |
connective tissue cell | 4 studies | 34% ± 8% | |
myofibroblast cell | 3 studies | 23% ± 9% | |
smooth muscle cell | 3 studies | 19% ± 5% |
Insufficient scRNA-seq data for expression of LOXL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3059.81 | 459 / 459 | 97% | 43.33 | 1086 / 1118 |
intestine | 99% | 2858.88 | 961 / 966 | 94% | 37.80 | 496 / 527 |
lung | 96% | 1289.76 | 554 / 578 | 87% | 31.94 | 1001 / 1155 |
ovary | 99% | 2006.61 | 178 / 180 | 81% | 19.21 | 350 / 430 |
stomach | 82% | 1137.94 | 295 / 359 | 98% | 35.38 | 279 / 286 |
uterus | 99% | 1663.89 | 169 / 170 | 80% | 37.38 | 365 / 459 |
bladder | 95% | 1317.05 | 20 / 21 | 83% | 27.28 | 420 / 504 |
esophagus | 80% | 2114.59 | 1153 / 1445 | 95% | 40.13 | 174 / 183 |
skin | 87% | 6854.81 | 1581 / 1809 | 87% | 32.87 | 411 / 472 |
pancreas | 63% | 391.80 | 207 / 328 | 94% | 49.10 | 168 / 178 |
thymus | 96% | 888.27 | 625 / 653 | 58% | 8.63 | 348 / 605 |
prostate | 97% | 1326.79 | 238 / 245 | 50% | 5.88 | 249 / 502 |
kidney | 69% | 602.26 | 61 / 89 | 77% | 44.42 | 694 / 901 |
adrenal gland | 66% | 427.60 | 170 / 258 | 58% | 15.03 | 133 / 230 |
adipose | 100% | 3700.96 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.41 | 1 / 1 |
blood vessel | 98% | 1538.49 | 1312 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 41.10 | 28 / 29 |
spleen | 96% | 831.44 | 232 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 23.01 | 36 / 45 |
heart | 78% | 959.70 | 675 / 861 | 0% | 0 | 0 / 0 |
brain | 24% | 137.47 | 621 / 2642 | 52% | 16.30 | 367 / 705 |
liver | 21% | 252.92 | 48 / 226 | 41% | 6.44 | 165 / 406 |
muscle | 31% | 206.54 | 249 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.61 | 4 / 80 |
peripheral blood | 1% | 8.44 | 12 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1902455 | Biological process | negative regulation of stem cell population maintenance |
GO_0001837 | Biological process | epithelial to mesenchymal transition |
GO_0018057 | Biological process | peptidyl-lysine oxidation |
GO_0032332 | Biological process | positive regulation of chondrocyte differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_0070828 | Biological process | heterochromatin organization |
GO_0036211 | Biological process | protein modification process |
GO_0043542 | Biological process | endothelial cell migration |
GO_0001666 | Biological process | response to hypoxia |
GO_0001935 | Biological process | endothelial cell proliferation |
GO_0010718 | Biological process | positive regulation of epithelial to mesenchymal transition |
GO_0046688 | Biological process | response to copper ion |
GO_0030199 | Biological process | collagen fibril organization |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005615 | Cellular component | extracellular space |
GO_0016020 | Cellular component | membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005604 | Cellular component | basement membrane |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0004720 | Molecular function | protein-lysine 6-oxidase activity |
GO_0070492 | Molecular function | oligosaccharide binding |
GO_0005507 | Molecular function | copper ion binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LOXL2 |
Protein name | Lysyl oxidase homolog 2 (EC 1.4.3.13) (Lysyl oxidase-like protein 2) (Lysyl oxidase-related protein 2) (Lysyl oxidase-related protein WS9-14) Lysyl oxidase homolog 2 (Lysyl oxidase-like protein 2) Lysyl oxidase like 2 Lysyl oxidase homolog (EC 1.4.3.13) |
Synonyms | |
Description | FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) . Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation . Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) . Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription . LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (By similarity). Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 . During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription . SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits . Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction . Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression . When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin . Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding . Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation (By similarity). . FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). . FUNCTION: Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). . |
Accessions | E5RHH3 ENST00000519243.1 ENST00000523833.2 E5RFE2 E5RJL2 ENST00000518878.5 R4GMS2 Q9Y4K0 ENST00000520871.1 ENST00000524168.1 H0YAP6 ENST00000518083.5 ENST00000520349.1 E5RFY0 W6I206 E5RI22 H0YAR1 ENST00000389131.8 ENST00000524144.5 W8QRJ0 |